Evidence map›Paper›PMID 41368499›Full record

ArticlePeerJ2025

Retrospective study on the clinical outcomes and characteristics of acute myeloid leukemia: different outcomes in the same risk group.

Fanqiao Meng, Maoyuan Xiang, Huan Xie, Yu Liu, Yan Qi, Dongfeng Zeng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fanqiao Meng *Department of Hematology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Maoyuan Xiang *Department of Hematology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Huan XieDepartment of Hematology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Yu LiuDepartment of Hematology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Yan QiDepartment of Hematology, Daping Hospital, The Third Military Medical University, Chongqing, China.
Dongfeng ZengDepartment of Hematology, Daping Hospital, The Third Military Medical University, Chongqing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Acute myeloid leukemia (AML) remains a prognostically heterogeneous malignancy despite advances in molecular risk stratification. While the 2022 European Leukemia Network (ELN) guidelines refine risk classification, their accuracy in predicting survival outcomes across genetic requires validation. Methods: We conducted a retrospective analysis of 154 newly diagnosed AML patients at Daping Hospital, integrating next-generation sequencing (NGS)-based genetic profiling, 2022 ELN risk classification, and clinical outcomes. Results: The most frequent mutations were Conclusions: The ELN risk classification demonstrate limitations in prognostication, particularly for patients with Trial registration: The study was registered on the Chinese clinical trial registry (ChiCTR) platform (No. ChiCTR2500096484).

Indexed as

Leukemia, Myeloid, AcuteAdolescentAdultAgedCCAAT-Enhancer-Binding ProteinsDioxygenasesDNA-Binding ProteinsDNA Methyltransferase 3AFemalefms-Like Tyrosine Kinase 3Hematopoietic Stem Cell TransplantationHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedMutationCCAAT-Enhancer-Binding ProteinsCEBPA protein, humanDioxygenasesDNA-Binding ProteinsDNA Methyltransferase 3ADNMT3A protein, humanFLT3 protein, humanfms-Like Tyrosine Kinase 3NPM1 protein, humanNucleophosminProto-Oncogene ProteinsTET2 protein, humanAcute myeloid leukemiaEuropean Leukemia NetworkGenetic heterogeneityPrognostic stratification

Identifiers

PMID41368499
PMCPMC12684409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.